uNTx、sBAP、BMD检测在恶性肿瘤骨转移中的诊断价值

Research on the clinical value of urinary NTx,serum BAP and BMD in patients with bone metastasis from malignant tumors

目的探讨恶性肿瘤骨转移患者尿Ⅰ型胶原交联氨基末端肽(uNTx)、血清骨源性碱性磷酸酶(sBAP)、骨密度(BMD)的变化及临床意义。方法采用酶联免疫吸附法测定53例恶性肿瘤骨转移患者(骨转移组)uNTx、sBAP水平,同时采用双能X线骨密度仪测量BMD,并以40例恶性肿瘤无骨转移患者作对照(无骨转移组)。结果骨转移组患者uNTx和sBAP均明显高于无骨转移组(P<0.05),骨转移患者uNTx和sBAP水平与骨转移数目有关(P<0.05),与骨痛程度无显著相关(P>0.05)。骨转移组BMD下降,但与无骨转移组比较差异无统计学意义(P<0.05)。结论骨代谢生化指标uNTx、sBAP对恶性肿瘤骨转移的早期诊断具有一定的价值且恶性肿瘤患者常伴有BMD降低。

Objective To evaluate the variance and clinical significance of urinary pyridinoline cross-linked N-telopeptides of Type Ⅰ collagen（uNTx） ,serum bone specific alkaline phosphates（sBAP） and Bone mineral density（BMD） in patients with bone metastasis malignant tumors .Methods The levels of 53 case patients′,who with bone metastasis ,uNTx and sBAP were measured by ELISA and BMD was detected by dual energy x-ray absorptiometer .40 cases of non-bone metastasis people was assayed .Results The levels of all bone markers in patients with bone metastasis was significantly higher than in the patients without bone metas-tasis（P＆lt;0 .05） .The levels of the two biomarkers showed a positive correlation with the number of metastatic loci in bone （P＆lt;0 .05） .But there was not significantly different between the levels of uNTx or sBAP with the severity of the bone pain （P＆gt;0 .05） . BMD decreased in patients with bone metastasis group ,but it was no difference in the non-bone metastasis（P＆gt;0 .05） .Conclusion uNTx and sBAP are helpful for early diagnosis and prevention of patients with bone metastasis from malignant tumors .Patients with malignant gumor is often accompanied by a decrease in BMD .